In a 64-year-old patient with severe dementia and confusion who is currently taking donepezil (Aricept) 10 mg at bedtime and memantine 10 mg twice daily, and who wanders into other patients' rooms while disoriented, what medication should be prescribed to reduce wandering and agitation?

Pharmacologic Management of Severe Agitation and Wandering in Dementia

For this 64-year-old patient with severe dementia, wandering, and disorientation already on donepezil and memantine, I recommend starting a low-dose atypical antipsychotic, specifically risperidone 0.25 mg at bedtime or quetiapine 12.5 mg twice daily, only after exhausting non-pharmacologic interventions.

Critical First Steps Before Prescribing

Before adding any medication to "slow her down," you must:

• Rule out reversible causes: Pain, urinary tract infection, constipation, medication side effects, environmental overstimulation
• Assess severity: Is the wandering dangerous? Is she at risk of harm or causing significant distress?
• Document failed non-pharmacologic interventions: Structured activities, environmental modifications (locked doors/gates), redirection techniques, Safe Return Program registration 1

Important caveat: The guideline explicitly states that wandering and pacing behaviors are not amenable to drug therapy 1. Medications should only target severe agitation, combativeness, or psychosis—not wandering itself.

Non-Pharmacologic Interventions (Must Try First)

1

• Register patient in Alzheimer's Association Safe Return Program
• Install safety locks on doors and gates
• Establish predictable daily routines
• Reduce environmental stimulation (noise, clutter, crowds)
• Use the "three R's" approach: Repeat, Reassure, Redirect
• Consider adult day care programs
• Scheduled toileting to prevent agitation from discomfort

When Pharmacologic Treatment Is Justified

Only prescribe antipsychotics if 2:

• Symptoms are severe, dangerous, or cause significant patient distress
• Non-pharmacologic interventions have been documented and failed
• Risk-benefit discussion completed with patient/family

Medication Recommendations

First-Line: Atypical Antipsychotics

Risperidone (Risperdal) 1:

• Start: 0.25 mg at bedtime
• Titrate: Slowly to maximum 2-3 mg/day in divided doses
• Advantages: Best evidence for severe psychomotor agitation and combativeness
• Caution: Extrapyramidal symptoms may occur at ≥2 mg/day

Quetiapine (Seroquel) 1, 3:

• Start: 12.5 mg twice daily
• Titrate: Up to maximum 200 mg twice daily
• Advantages: More sedating (may help with nighttime wandering), lowest adverse event rate in older adults (OR 0.27 vs haloperidol) 3
• Caution: Monitor for orthostatic hypotension, especially initially

Olanzapine (Zyprexa) 1:

• Start: 2.5 mg at bedtime
• Titrate: Up to maximum 10 mg/day in divided doses
• Advantages: Generally well tolerated

Alternative: Mood Stabilizers (If Antipsychotics Fail)

Trazodone 1:

• Start: 25 mg at bedtime
• Titrate: Up to 200-400 mg/day in divided doses
• Use: For severe agitated, repetitive, combative behaviors
• Caution: Avoid in patients with premature ventricular contractions

Avoid in Older Adults

Benzodiazepines (especially midazolam): Associated with 5.25 times higher risk of adverse events in older adults with agitation 3. Can cause paradoxical agitation in 10% of patients, plus tolerance, addiction, and cognitive worsening 1.

Typical antipsychotics (haloperidol): Should be avoided due to 50% risk of tardive dyskinesia after 2 years in elderly patients, plus significant cardiovascular and extrapyramidal side effects 1.

Optimizing Current Regimen

Consider timing adjustment: Move donepezil from bedtime to morning, as it can cause insomnia and may worsen nighttime agitation 4.

Memantine dosing is appropriate: She's already on 10 mg BID, which is the target dose for moderate-to-severe dementia 5. Evidence shows memantine combined with donepezil reduces agitation/aggression in patients with baseline behavioral symptoms 6, 7, 8, 9.

Monitoring and Reassessment

2

• Use quantitative measures to track response (e.g., Neuropsychiatric Inventory)
• 4-week trial rule: If no response after 4 weeks at adequate dose, taper and discontinue
• Reassess every 4-6 months: Attempt dose reduction to determine if continued treatment is necessary
• Monitor for side effects: Sedation, falls, extrapyramidal symptoms, metabolic changes

Critical Safety Warnings

• Black box warning: Antipsychotics increase mortality risk in elderly patients with dementia 2
• Start low, go slow: Use lowest effective dose
• Time-limited use: Reassess need every 4-6 months
• Document thoroughly: Rationale for use, failed alternatives, informed consent discussion

What NOT to Do

• Do not prescribe medications solely to control wandering—this is ineffective and potentially harmful 1
• Do not use benzodiazepines as first-line in older adults with dementia 3
• Do not continue antipsychotics indefinitely without periodic reassessment 2
• Do not skip non-pharmacologic interventions—they may reduce medication needs 1